Publication Name	World Journal of Clinical Cases
Manuscript ID	92251
Country	China

Received	2024-02-21 09:25
Peer-Review Started	2024-02-21 09:25
To Make the First Decision
Return for Revision	2024-04-04 08:37
Revised	2024-04-09 09:04
Second Decision	2024-04-18 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-04-18 08:29
Articles in Press	2024-04-18 08:29
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-05-30 07:59
Publish the Manuscript Online	2024-06-18 09:29

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Randomized Controlled Trial
Article Title	Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia
Manuscript Source	Unsolicited Manuscript
All Author List	Meng-Jiao Lin, Shu-Bin Zou and Bai-Xiang Zhu
ORCID	Author(s) ORCID Number Meng-Jiao Lin http://orcid.org/0009-0008-9595-2800 Bai-Xiang Zhu http://orcid.org/0009-0005-4616-9535
Funding Agency and Grant Number
Corresponding Author	Bai-Xiang Zhu, MM, Attending Doctor, Department of Cardiovascular, Harbin 242 Hospital, No. 3 Weijian Street, Pingfang District, Harbin 150066, Heilongjiang Province, China. farc364@163.com
Key Words	Dapagliflozin; Hyperuricemia; Chronic heart failure; Sodium-glucose cotransporter-2 inhibitor; Uric acid levels; Cardiovascular mortality
Core Tip	Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor inhibitor, significantly lowers serum uric acid levels and improves clinical outcomes in patients with chronic heart failure (CHF) and hyperuricemia. This randomized trial demonstrates significant decreases in serum uric acid levels, improvements in left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide levels, and quality of life scores compared with placebo. Furthermore, dapagliflozin reduces the risk of cardiovascular death and hospitalization for heart failure. Adverse events, except for a higher incidence of genital infection in the dapagliflozin group, were similar. Thus, dapagliflozin is a promising therapeutic option for CHF patients with hyperuricemia.
Publish Date	2024-06-18 09:29
Citation	<p>Lin MJ, Zou SB, Zhu BX. Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia. <i>World J Clin Cases</i> 2024; 12(18): 3468-3475</p>
URL	https://www.wjgnet.com/2307-8960/full/v12/i18/3468.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i18.3468

Full Article (PDF)	WJCC-12-3468-with-cover.pdf
CONSORT 2010 Statement	92251-CONSORT-2010-statement.pdf
Manuscript File	92251_Auto_Edited-YJP.docx
Answering Reviewers	92251-answering-reviewers.pdf
Audio Core Tip	92251-audio.m4a
Biostatistics Review Certificate	92251-biostatistics-statement.pdf
Clinical Trial Registration Statement	92251-clinical-trial-registration-statement.pdf
Conflict-of-Interest Disclosure Form	92251-conflict-of-interest-statement.pdf
Copyright License Agreement	92251-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	92251-foundation-statement.pdf
Signed Informed Consent Form(s) or Document(s)	92251-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	92251-institutional-review-board-statement.pdf
Peer-review Report	92251-peer-reviews.pdf
Scientific Misconduct Check	92251-scientific-misconduct-check.png
Scientific Editor Work List	92251-scientific-editor-work-list.pdf
CrossCheck Report	92251-crosscheck-report.pdf